Medicenna Advances MDNA11 Melanoma Trial in Italy
TORONTO, Ontario, May 13, 2026 Medicenna Therapeutics announced that the first patient has been enrolled and dosed in the...
AI drug discovery artificial intelligence Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
TORONTO, Ontario, May 13, 2026 Medicenna Therapeutics announced that the first patient has been enrolled and dosed in the...
MILWAUKEE, Feb. 21, 2026 — New research presented at the 2026 Annual Meeting of the American Academy of Allergy,...
SAN DIEGO & RIYADH — February 20, 2026 — Immunotherapy innovator ImmunityBio has announced a strategic partnership with regional...
SAN FRANCISCO, Feb. 13, 2026 — Nektar Therapeutics announced the successful closing of a $460 million underwritten public offering,...
